|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11534395||BAUSCH AND LOMB INC||Ophthalmic suspension composition|| |
(12 years from now)
|US10596107||BAUSCH AND LOMB INC||Ophthalmic suspension composition|| |
(13 years from now)
Lotemax Sm is owned by Bausch And Lomb Inc.
Lotemax Sm contains Loteprednol Etabonate.
Lotemax Sm has a total of 2 drug patents out of which 0 drug patents have expired.
Lotemax Sm was authorised for market use on 22 February, 2019.
Lotemax Sm is available in gel;ophthalmic dosage forms.
Lotemax Sm can be used as treatment of post-operative inflammation and pain following ocular surgery.
The generics of Lotemax Sm are possible to be released after 23 December, 2036.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Strength (NS)||Feb 22, 2022|
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic